Avelumab maintenance following first-line platinum-based chemotherapy in advanced urothelial carcinoma from ASCO 2020 as reported by Clinical Care Options (CCO)
Data presented at ASCO 2020 on exploratory biomarker analyses from the phase III CheckMate 214 trial, as reported by Clinical Care Options (CCO)
ASCO 2020 data on treatment with nivolumab plus brentuximab vedotin in standard-risk young patients with R/R classical Hodgkin lymphoma as reported by Clinical Care Options (CCO)
Results from BYLieve Cohort A with alpelisib plus fulvestrant in PIK3CA¬-mutated HR+/HER2- advanced breast cancer post-CDK4/6i, from ASCO 2020 as reported by Clinical Care Options (CCO)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.